Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

29.93
-0.2559-0.85%
Pre-market: 30.260.3271+1.09%08:48 EDT
Volume:9K
Turnover:279.68K
Market Cap:55.97M
PE:- -
High:30.22
Open:30.22
Low:29.84
Close:30.19
52wk High:37.15
52wk Low:27.34
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.84
T/O Rate:0.50%
Dividend:0.41
Dividend Rate:1.37%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Market Chatter: Novo Nordisk CEO Eyes M&A to Fill Gaps in Drug Portfolio

MT Newswires Live
·
Sep 22

Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’

TIPRANKS
·
Sep 22

Novo Nordisk (0QIU) Receives a Hold from Berenberg Bank

TIPRANKS
·
Sep 22

Novo Nordisk Investors Remain Nervous, but Share Drop an Overreaction

Dow Jones
·
Sep 22

Novo Nordisk's Underwhelming Investor Day Met with Punishing Response

Dow Jones
·
Sep 22

Novo Nordisk's Share Fall After Investor Day Seems Harsh

Dow Jones
·
Sep 22

Novo Nordisk Investor Day Offered Little to Excite

Dow Jones
·
Sep 22

Novo Nordisk Highlights Building Blocks, but More Data Needed to Reassure Investors

Dow Jones
·
Sep 22

Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site

MT Newswires Live
·
Sep 22

Eli Lilly: Breaks Ground on Fifth U.S. API Manufacturing Site in Houston

THOMSON REUTERS
·
Sep 22

Eli Lilly: Houston Facility to Manufacture Active Pharmaceutical Ingredients for Medicines Like Foundayo

THOMSON REUTERS
·
Sep 22

NYSE Net Change Percentage Gainers & Losers

Dow Jones
·
Sep 22

NYSE Most Active Issues

Dow Jones
·
Sep 22

Pharmaceutical Companies Push Trump Administration to Protect China Deals

Dow Jones
·
Sep 22

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Sector Update: Healthcare

MT Newswires Live
·
Sep 22

Viking Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since September 2023

Dow Jones
·
Sep 22

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Pfizer’s Rimegepant Trial Targets Chronic Migraine Market Upside

TIPRANKS
·
Sep 22

Pfizer Advances PF-07799544 With Completion of Key Phase 1 Study

TIPRANKS
·
Sep 22